{"product_id":"new-product-610040","title":"Magnetic Luminex Assay Kit for Terminal Complement Complex C5b-9 (C5b-9) ,etc.","description":"\u003cp data-mce-fragment=\"1\"\u003eProduct No.\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eLMC350Hu\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eOrganism Species\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eHomo sapiens (Human).\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eSample Type\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eserum, plasma and other biological fluids\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eTest Method\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eDouble-antibody Sandwich\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eAssay Length\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e3.5h\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eDetection Range\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e0.08-80ng\/mL\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eSensitivity\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eThe minimum detectable dose of this kit is typically less than 0.027 ng\/mL.\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003eUOM\u003c\/p\u003e\n\u003cp data-mce-fragment=\"1\"\u003e1Plex 2Plex 3Plex 4Plex 5Plex 6Plex 7Plex 8Plex\u003c\/p\u003e\n\u003cdiv class=\"product_left\"\u003e\n\u003ch3\u003eSpecificity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThis assay has high sensitivity and excellent specificity for detection of Terminal Complement Complex C5b-9 (C5b-9) ,etc..\u003cbr\u003eNo significant cross-reactivity or interference between Terminal Complement Complex C5b-9 (C5b-9) ,etc. and analogues was observed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eRecovery\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eMatrices listed below were spiked with certain level of recombinant Terminal Complement Complex C5b-9 (C5b-9) ,etc. and the recovery rates were calculated by comparing the measured value to the expected amount of Terminal Complement Complex C5b-9 (C5b-9) ,etc. in samples.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMatrix\u003c\/td\u003e\n\u003ctd\u003eRecovery range (%)\u003c\/td\u003e\n\u003ctd\u003eAverage(%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e84-105\u003c\/td\u003e\n\u003ctd\u003e99\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e83-101\u003c\/td\u003e\n\u003ctd\u003e95\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e78-102\u003c\/td\u003e\n\u003ctd\u003e92\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003esodium citrate plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e98-105\u003c\/td\u003e\n\u003ctd\u003e101\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003ePrecision\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eIntra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Terminal Complement Complex C5b-9 (C5b-9) ,etc. were tested 20 times on one plate, respectively.\u003cbr\u003eInter-assay Precision (Precision between assays): 3 samples with low, middle and high level Terminal Complement Complex C5b-9 (C5b-9) ,etc. were tested on 3 different plates, 8 replicates in each plate.\u003cbr\u003eCV(%) = SD\/meanX100\u003cbr\u003eIntra-Assay: CV\u0026lt;10%\u003cbr\u003eInter-Assay: CV\u0026lt;12%\u003cbr\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eLinearity\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe linearity of the kit was assayed by testing samples spiked with appropriate concentration of Terminal Complement Complex C5b-9 (C5b-9) ,etc. and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSample\u003c\/td\u003e\n\u003ctd\u003e1:2\u003c\/td\u003e\n\u003ctd\u003e1:4\u003c\/td\u003e\n\u003ctd\u003e1:8\u003c\/td\u003e\n\u003ctd\u003e1:16\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eserum(n=5)\u003c\/td\u003e\n\u003ctd\u003e79-90%\u003c\/td\u003e\n\u003ctd\u003e90-102%\u003c\/td\u003e\n\u003ctd\u003e82-102%\u003c\/td\u003e\n\u003ctd\u003e99-105%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDTA plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e84-91%\u003c\/td\u003e\n\u003ctd\u003e79-93%\u003c\/td\u003e\n\u003ctd\u003e98-105%\u003c\/td\u003e\n\u003ctd\u003e87-102%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eheparin plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e79-88%\u003c\/td\u003e\n\u003ctd\u003e93-101%\u003c\/td\u003e\n\u003ctd\u003e84-92%\u003c\/td\u003e\n\u003ctd\u003e87-94%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003esodium citrate plasma(n=5)\u003c\/td\u003e\n\u003ctd\u003e83-102%\u003c\/td\u003e\n\u003ctd\u003e96-105%\u003c\/td\u003e\n\u003ctd\u003e86-94%\u003c\/td\u003e\n\u003ctd\u003e87-99%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3\u003eStability\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003eThe stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.\u003cbr\u003eTo minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch3\u003eReagents and materials provided\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"reagent_div\"\u003e\n\u003ctable class=\"reagent_table\"\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eQuantity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e96-well plate\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003ePlate sealer for 96 wells\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Mixed Standard\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003eStandard Diluent\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Mixed Magnetic beads (22#:C5b-9)\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003eAnalysis buffer\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-Mixed Detection Reagent A\u003c\/td\u003e\n\u003ctd\u003e1×120μL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent A\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDetection Reagent B (PE-SA)\u003c\/td\u003e\n\u003ctd\u003e1×120μL\u003c\/td\u003e\n\u003ctd\u003eAssay Diluent B\u003c\/td\u003e\n\u003ctd\u003e1×12mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSheath Fluid\u003c\/td\u003e\n\u003ctd\u003e1×10mL\u003c\/td\u003e\n\u003ctd\u003eWash Buffer (30 × concentrate)\u003c\/td\u003e\n\u003ctd\u003e1×20mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstruction manual\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ch3\u003eAssay procedure summary\u003c\/h3\u003e\n\u003cdiv\u003e\n\u003cp\u003e1. Preparation of standards, reagents and samples before the experiment;\u003cbr\u003e2. Add 100μL standard or sample to each well,\u003cbr\u003e    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;\u003cbr\u003e3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;\u003cbr\u003e4. Wash plate on magnetic frame for three times;\u003cbr\u003e5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;\u003cbr\u003e6. Wash plate on magnetic frame for three times;\u003cbr\u003e7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cul class=\"product_increment\"\u003e\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_reference\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eMagazine\u003c\/td\u003e\n\u003ctd\u003eCitations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Biomedical Materials Research Part A\u003c\/td\u003e\n\u003ctd\u003eEffect of thiol functionalization on the hemo-compatibility of PLGA nanoparticles\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jbm.a.33220\/full\" target=\"_blank\"\u003eWiley: source\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThe Journal of Clinical Investigation\u003c\/td\u003e\n\u003ctd\u003eComplement component 5 contributes to poor disease outcome in humans and mice with pneumococcal meningitis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3195471\/\" target=\"_blank\"\u003ePubMed: PMC3195471\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eColloids and Surfaces B: Biointerfaces\u003c\/td\u003e\n\u003ctd\u003eGlucosylated polymeric nanoparticles: A sweetened approach against blood compatibility paradox\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0927776513001720\" target=\"_blank\"\u003eScienceDirect: S0927776513001720\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePerfusion\u003c\/td\u003e\n\u003ctd\u003eThe effect of normovolemic modified ultrafiltration on inflammatory mediators, endotoxins, terminal complement complexes and clinical outcome in high-risk cardiac surgery patients\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23429100\" target=\"_blank\"\u003ePubmed: 23429100\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNephrology Dialysis Transplantation\u003c\/td\u003e\n\u003ctd\u003eThe efficacy of recombinant human soluble thrombomodulin for the treatment of shiga toxin associated hemolytic uremic syndrome model mice\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25694534\" target=\"_blank\"\u003ePubmed:25694534\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ejournal of neuroinflammation\u003c\/td\u003e\n\u003ctd\u003eAdjuvant treatment with dexamethasone plus anti-C5 antibodies improves outcome of experimental pneumococcal meningitis: a randomized controlled trial\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26272468\" target=\"_blank\"\u003ePubMed: 26272468\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJ Thromb Haemost\u003c\/td\u003e\n\u003ctd\u003eThrombin‐activatable fibrinolysis inhibitor influences disease severity in humans and mice with pneumococcal meningitis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26340319\" target=\"_blank\"\u003ePubMed: 26340319\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital Repository\u003c\/td\u003e\n\u003ctd\u003eDosagem de frações ativadas do sistema complemento em empiema induzido em ratos\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"http:\/\/www.lume.ufrgs.br\/bitstream\/handle\/10183\/150680\/001009027.pdf?sequence=1\u0026amp;locale-attribute=en\" target=\"_blank\"\u003e10183\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJ Neuroinflammation. \u003c\/td\u003e\n\u003ctd\u003eMannose-binding lectin-associated serine protease 2 (MASP-2) contributes to poor disease outcome in humans and mice with pneumococcal meningitis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5234106\/\" target=\"_blank\"\u003ePMC5234106\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer Letters\u003c\/td\u003e\n\u003ctd\u003eComplement C5a\/C5aR pathway potentiates the pathogenesis Q5 of gastric cancer by down-regulating p21 expression\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29031586\" target=\"_blank\"\u003epubmed:29031586\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003c\/td\u003e\n\u003ctd\u003eEffects of immunoadsorption combined with membrane filtration on complement markers–Results of a randomized, controlled, crossover study\u003ca rel=\"nofollow\" href=\"https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/tri.13431\" target=\"_blank\"\u003e\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJournal of Neuroinflammation\u003c\/td\u003e\n\u003ctd\u003eComplement factor H contributes to mortality in humans and mice with bacterial meningitis\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31883521\/\" target=\"_blank\"\u003ePubmed: 31883521\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFASEB J\u003c\/td\u003e\n\u003ctd\u003eC‐reactive protein inhibits C3a\/C3aR‐dependent podocyte autophagy in favor of diabetic kidney disease\u003cspan\u003e \u003c\/span\u003e\u003ca rel=\"nofollow\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35503088\/\" target=\"_blank\"\u003ePubmed:35503088\u003c\/a\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product_relation\"\u003e\n\u003ctable\u003e\n\u003ctbody\u003e\n\u003ctr class=\"first_tr\"\u003e\n\u003ctd class=\"td_1\"\u003eCatalog No.\u003c\/td\u003e\n\u003ctd class=\"td_2\"\u003eRelated products for research use of Homo sapiens (Human) Organism species\u003c\/td\u003e\n\u003ctd class=\"td_3\"\u003eApplications (RESEARCH USE ONLY!)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSEC350Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/SEC350Hu.html\"\u003eELISA Kit for Terminal Complement Complex C5b-9 (C5b-9)\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eEnzyme-linked immunosorbent assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLMC350Hu\u003c\/td\u003e\n\u003ctd\u003e\u003ca href=\"https:\/\/www.cloud-clone.com\/products\/LMC350Hu.html\"\u003eMagnetic Luminex Assay Kit for Terminal Complement Complex C5b-9 (C5b-9) ,etc.\u003c\/a\u003e\u003c\/td\u003e\n\u003ctd\u003eMagnetic Luminex Assay for Antigen Detection.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e","brand":"Cloud-clone","offers":[{"title":"0.08-80ng\/mL \/ 96T \/ typically less than 0.027 ng\/mL","offer_id":47562708910360,"sku":"LMC350Hu","price":840.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/products\/LMC350Hu_49cc465f-7e10-4b3e-bec3-e9d7713ce3d1.jpg?v=1705903860","url":"https:\/\/danabiosci.com\/products\/new-product-610040","provider":"Dana Bioscience","version":"1.0","type":"link"}